Korro Bio, Inc.
Description
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About
CEO
Mr. Ram Aiyar MBA, Ph.D.
Employees
101
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
One Kendall Square, Cambridge, MA 02139, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 12, 2025 | — | — | — | — |
| May 12, 2025 | — | — | — | — |
| Mar 24, 2025 | — | — | — | — |
| Nov 13, 2024 | -2.61 | -2.26 | 0.35 | -13.41% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 6 |
| Average estimate | — | -2.69 | — | -9.73 |
| Low estimate | — | -3.12 | — | -11.60 |
| High estimate | — | -2.39 | — | -8.31 |
| Last year EPS | — | -2.44 | — | -9.22 |
[stock_revenue_estimate]
Growth estimates
Current qtr
94.170%
Next qtr. (Mar 2025)
-7.170%
Current year
82.670%
Next year (Dec 2025)
-5.780%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total reported revenue | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating expense | |||
| Research & development | 57.25M | 42.20M | 23.81M |
| Selling general and admin | 27.28M | 16.80M | 11.69M |
| Other operating expenses | — | — | — |
| Operating income | -84.53M | -59.00M | -35.49M |
| Non operating interest income | |||
| Income | — | 947,000 | — |
| Expense | — | 118,000 | — |
| Other income expense | 3.39M | 976,000 | 13.54M |
| Pretax income | -81.15M | -58.02M | -21.96M |
| Tax provision | 27,000 | 10,000 | 2,000 |
| Net income | -81.17M | -58.03M | -21.96M |
| Basic EPS | -53.08 | -7.25 | -2.74 |
| Diluted EPS | -53.08 | -7.25 | -2.74 |
| Basic average shares | 1.53M | 8.00M | 8.00M |
| Diluted average shares | 1.53M | 8.00M | 8.00M |
| EBITDA | -80.90M | -56.49M | -33.90M |
| Net income from continuing op. | -81.17M | -58.03M | -21.96M |
| Minority interests | — | — | — |
| Preferred stock dividends | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 221.66M | 73.74M | 127.58M |
| Current assets | |||
| Cash | — | — | — |
| Cash equivalents | — | — | — |
| Cash and cash equivalents | 166.15M | 36.33M | 83.49M |
| Other short term investments | — | 18.92M | 35.04M |
| Accounts receivable | — | — | — |
| Other receivables | — | — | — |
| Inventory | — | — | — |
| Prepaid assets | — | — | — |
| Restricted cash | 3.56M | 603,000 | — |
| Assets held for sale | — | — | — |
| Hedging assets | — | — | — |
| Other current assets | 3.02M | 1.23M | 1.24M |
| Non current assets | |||
| Properties | 38.34M | 10.47M | 4.36M |
| Land and improvements | — | — | — |
| Machinery furniture equipment | 722,000 | 690,000 | 312,000 |
| Construction in progress | 8.24M | 2.05M | 1.33M |
| Leases | 3.36M | 2.94M | 2.88M |
| Accumulated depreciation | -7.84M | -4.26M | -1.74M |
| Goodwill | — | — | — |
| Investment properties | — | — | — |
| Financial assets | — | — | — |
| Intangible assets | — | — | — |
| Investments and advances | — | — | — |
| Other non current assets | 6.12M | 4.77M | 659,000 |
| Total liabilities | 51.75M | 172.77M | 169.78M |
| Current liabilities | |||
| Accounts payable | 7.28M | 2.61M | 789,000 |
| Accrued expenses | 1.47M | 344,000 | 440,000 |
| Short term debt | 1.99M | 2.92M | — |
| Deferred revenue | — | — | 939,000 |
| Tax payable | — | — | — |
| Pensions | 7.90M | 2.62M | 2.28M |
| Other current liabilities | 842,000 | 207,000 | 497,000 |
| Non current liabilities | |||
| Long term debt | 31.22M | 209,000 | — |
| Provision for risks and charges | — | — | — |
| Deferred liabilities | — | — | — |
| Derivative product liabilities | — | — | — |
| Other non current liabilities | 1.05M | — | 2,000 |
| Shareholders equity | |||
| Common stock | 8,000 | — | 5,000 |
| Retained earnings | -183.01M | -101.83M | -43.80M |
| Other shareholders equity | — | -5,000 | -7,000 |
| Total shareholders equity | 169.91M | -99.03M | -42.21M |
| Additional paid in capital | 352.91M | 2.81M | 1.60M |
| Treasury stock | — | — | — |
| Minority interest | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -81.17M | -58.03M | -21.96M |
| Depreciation | 3.63M | 2.51M | 1.60M |
| Deferred Taxes | — | — | — |
| Stock-Based Compensation | 2.38M | 1.14M | 807,000 |
| Other Non-Cash Items | 3.61M | 1.51M | -13.47M |
| Accounts Receivable | — | — | — |
| Accounts Payable | 3.10M | 1.76M | 56,000 |
| Other Assets & Liabilities | -646,000 | -2.32M | -715,000 |
| Operating Cash Flow | -69.10M | -53.43M | -33.69M |
| Investing Activities | |||
| Capital Expenditures | -7.84M | -5.21M | -4.43M |
| Net Intangibles | — | — | — |
| Net Acquisitions | — | — | — |
| Purchase of Investments | — | -37.21M | -35.07M |
| Sale of Investments | 19.00M | 53.49M | — |
| Investing Cash Flow | 11.16M | 11.06M | -39.50M |
| Financing Activities | |||
| Long-Term Debt Issuance | — | — | — |
| Long-Term Debt Payments | — | — | — |
| Other Financing Charges | 24.35M | -44,000 | -30,000 |
| Financing Cash Flow | 187.06M | -44,000 | 115.92M |
| Other Cash Details | |||
| End Cash Position | 173.12M | 41.48M | 84.04M |
| Income Tax Paid | 27,000 | 11,000 | — |
| Interest Paid | — | — | — |
| Free Cash Flow | -75.12M | -58.86M | -36.54M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| AB Cap Fd.-AB Small Cap Growth Port | Dec 31, 2024 | 315,981 | 12.35M | 3.37% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 291,299 | 11.39M | 3.11% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 171,100 | 6.69M | 1.83% |
| Fidelity Growth Company Fund | Nov 30, 2024 | 137,330 | 5.37M | 1.47% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 80,910 | 3.16M | 0.86% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 61,933 | 2.42M | 0.66% |
| Fidelity Small Cap Growth Fund | Oct 31, 2024 | 51,600 | 2.02M | 0.55% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 43,546 | 1.70M | 0.46% |
| Fidelity Growth Company K6 Fund | Nov 30, 2024 | 35,159 | 1.37M | 0.38% |
| Franklin Strategic Series-Franklin Biotechnology Discove | Oct 31, 2024 | 33,800 | 1.32M | 0.36% |
Article
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
Nov 21, 2024
Article
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110
Nov 21, 2024
Article
Korro to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference.
Nov 14, 2024
